541 related articles for article (PubMed ID: 33280030)
1. Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura.
Goshua G; Sinha P; Hendrickson JE; Tormey C; Bendapudi PK; Lee AI
Blood; 2021 Feb; 137(7):969-976. PubMed ID: 33280030
[TBL] [Abstract][Full Text] [Related]
2. Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.
Scully M; Cataland SR; Peyvandi F; Coppo P; Knöbl P; Kremer Hovinga JA; Metjian A; de la Rubia J; Pavenski K; Callewaert F; Biswas D; De Winter H; Zeldin RK;
N Engl J Med; 2019 Jan; 380(4):335-346. PubMed ID: 30625070
[TBL] [Abstract][Full Text] [Related]
3. Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.
Peyvandi F; Scully M; Kremer Hovinga JA; Cataland S; Knöbl P; Wu H; Artoni A; Westwood JP; Mansouri Taleghani M; Jilma B; Callewaert F; Ulrichts H; Duby C; Tersago D;
N Engl J Med; 2016 Feb; 374(6):511-22. PubMed ID: 26863353
[TBL] [Abstract][Full Text] [Related]
4. Real-world experience with caplacizumab in the management of acute TTP.
Dutt T; Shaw RJ; Stubbs M; Yong J; Bailiff B; Cranfield T; Crowley MP; Desborough M; Eyre TA; Gooding R; Grainger J; Hanley J; Haughton J; Hermans J; Hill Q; Humphrey L; Lowe G; Lyall H; Mohsin M; Nicolson PLR; Priddee N; Rampotas A; Rayment R; Rhodes S; Taylor A; Thomas W; Tomkins O; Van Veen JJ; Lane S; Toh CH; Scully M
Blood; 2021 Apr; 137(13):1731-1740. PubMed ID: 33150355
[TBL] [Abstract][Full Text] [Related]
5. A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP.
Coppo P; Bubenheim M; Azoulay E; Galicier L; Malot S; Bigé N; Poullin P; Provôt F; Martis N; Presne C; Moranne O; Benainous R; Dossier A; Seguin A; Hié M; Wynckel A; Delmas Y; Augusto JF; Perez P; Rieu V; Barbet C; Lhote F; Ulrich M; Rumpler AC; de Witte S; Krummel T; Veyradier A; Benhamou Y
Blood; 2021 Feb; 137(6):733-742. PubMed ID: 33150928
[TBL] [Abstract][Full Text] [Related]
6. Caplacizumab: an anti-von Willebrand factor antibody for the treatment of thrombotic thrombocytopenic purpura.
Hollifield AL; Arnall JR; Moore DC
Am J Health Syst Pharm; 2020 Jul; 77(15):1201-1207. PubMed ID: 32588878
[TBL] [Abstract][Full Text] [Related]
7. A critical evaluation of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura.
Gómez-Seguí I; Fernández-Zarzoso M; de la Rubia J
Expert Rev Hematol; 2020 Nov; 13(11):1153-1164. PubMed ID: 32876503
[No Abstract] [Full Text] [Related]
8. Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura.
Peyvandi F; Scully M; Kremer Hovinga JA; Knöbl P; Cataland S; De Beuf K; Callewaert F; De Winter H; Zeldin RK
J Thromb Haemost; 2017 Jul; 15(7):1448-1452. PubMed ID: 28445600
[TBL] [Abstract][Full Text] [Related]
9. Caplacizumab for relapsing thrombotic thrombocytopenic purpura.
Kaczmarek V; Holle J; Astudillo R; Kempf C; Bufler P; Müller D
Pediatr Nephrol; 2019 Sep; 34(9):1625-1628. PubMed ID: 31177334
[TBL] [Abstract][Full Text] [Related]
10. Role of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura.
Reid JH; Durant KM; Chen SL; Perissinotti AJ; King R; Khoriaty R; Marini BL
J Oncol Pharm Pract; 2020 Oct; 26(7):1695-1702. PubMed ID: 32605495
[TBL] [Abstract][Full Text] [Related]
11. Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura.
Elverdi T; Eskazan AE
Drug Des Devel Ther; 2019; 13():1251-1258. PubMed ID: 31118566
[TBL] [Abstract][Full Text] [Related]
12. Successful use of a second course of caplacizumab in relapsed thrombotic thrombocytopenic purpura.
Shaffer J; Grove A
Platelets; 2022 Jul; 33(5):790-791. PubMed ID: 34565299
[TBL] [Abstract][Full Text] [Related]
13. Successful management of three patients with autoimmune thrombotic thrombocytopenic purpura with paradigm-changing therapy: Caplacizumab, steroids, plasma exchange, rituximab, and intravenous immunoglobulins (CASPERI).
Cid J; Pérez-Valencia AI; Torrente MÁ; Ávarez-Larrán A; Díaz-Ricart M; Esteve J; Lozano M
Transfus Apher Sci; 2021 Feb; 60(1):103011. PubMed ID: 33221124
[TBL] [Abstract][Full Text] [Related]
14. Caplacizumab: a change in the paradigm of thrombotic thrombocytopenic purpura treatment.
le Besnerais M; Veyradier A; Benhamou Y; Coppo P
Expert Opin Biol Ther; 2019 Nov; 19(11):1127-1134. PubMed ID: 31359806
[No Abstract] [Full Text] [Related]
15. Thrombotic Thrombocytopenic Purpura: Beyond Empiricism and Plasma Exchange.
Tsai HM
Am J Med; 2019 Sep; 132(9):1032-1037. PubMed ID: 30928346
[TBL] [Abstract][Full Text] [Related]
16. Caplacizumab Model-Based Dosing Recommendations in Pediatric Patients With Acquired Thrombotic Thrombocytopenic Purpura.
Bergstrand M; Hansson E; Delaey B; Callewaert F; De Passos Sousa R; Sargentini-Maier ML
J Clin Pharmacol; 2022 Mar; 62(3):409-421. PubMed ID: 34699078
[TBL] [Abstract][Full Text] [Related]
17. Cost analysis of the impact of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura from a US hospital perspective.
Pollissard L; Leinwand BI; Fournier M; Pham HP
J Med Econ; 2021; 24(1):1178-1184. PubMed ID: 34643472
[TBL] [Abstract][Full Text] [Related]
18. Caplacizumab: First Global Approval.
Duggan S
Drugs; 2018 Oct; 78(15):1639-1642. PubMed ID: 30298461
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of caplacizumab in the treatment of thrombotic thrombocytopenic purpura: a systematic review and meta-analysis.
He J; Qi J; Han H; Xu X; Li X; Song X; Han Y
Expert Rev Hematol; 2023 May; 16(5):377-385. PubMed ID: 37045600
[TBL] [Abstract][Full Text] [Related]
20. Fatal cerebral hemorrhage in a patient with thrombotic thrombocytopenic purpura with a normal platelet count during treatment with caplacizumab.
Ditzel K; Mons DJ; Fijnheer R
Platelets; 2022 Apr; 33(3):484-485. PubMed ID: 33979560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
